A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft

Leukemia and Lymphoma

Volumn 48, Issue 5, 2007, Pages 881-884

  Thomson, K J ^a   Peggs, K S ^a   Blundell, E ^b   Goldstone, A H ^a   Linch, D C ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

Autologous stem cell transplantation; Hodgkin's lymphoma; Relapse

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PROCARBAZINE; THIOTEPA; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DYING; FEMALE; HODGKIN DISEASE; HUMAN; MALE; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MELPHALAN; PODOPHYLLOTOXIN; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 34547423172     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701216394     Document Type: Article

References (16)

1. Johnston, L. J. and Horning, S. J. (2000) Autologous hematopoietic cell transplantation in Hodgkin's disease. Biol Blood Marrow Transplant, 6, pp. 289-300.
2. Tarella, C., Cuttica, A., Vitolo, U., Liberati, M., Nicola, M Di and Cortelazzo, S. (2003) High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer, 97, pp. 2748-2759.
3. Linch, D. C., Winfield, D., Goldstone, A. H., Moir, D., Hancock, B. and McMillan, A. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet, 341, pp. 1051-1054.
4. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M. and Haenel, M. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet, 359, pp. 2065-2071.
5. Vose, J. M., Bierman, P. J., Anderson, J. R., Kessinger, A., Pierson, J. and Nelson, J. (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up. Blood, 80, pp. 2142-2148.
6. Shamash, J., Lee, S. M., Radford, J. A., Rohatiner, A. Z., Chang, J. and Morgenstern, G. R. (2000) Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: A two centre study. Ann Oncol, 11, pp. 715-719.
7. Santoro, A., Bredenfeld, H., Devizzi, L., Tesch, H., Bonfante, V. and Viviani, S. (2000) Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol, 18, pp. 2615-2619.
8. Anderson, J. E., Litzow, M. R., Appelbaum, F. R., Schoch, G., Fisher, L. D. and Buckner, C. D. (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol, 11, pp. 2342-2350.
9. Gajewski, J. L., Phillips, G. L., Sobocinski, K. A., Armitage, J. O., Gale, R. P. and Champlin, R. E. (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol, 14, pp. 572-578.
10. Milpied, N., Fielding, A. K., Pearce, R. M., Ernst, P. and Goldstone, A. H. (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol, 14, pp. 1291-1296.
11. Peggs, K. S., Hunter, A., Chopra, R., Parker, A., Mahendra, P. and Milligan, D. (2005) Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet, 365, pp. 1934-1941.
12. Avalos, B. R. and Copelan, E. A. (1993) Second autologous bone marrow transplantation in Hodgkin's disease. Bone Marrow Transplant, 12, pp. 665-667.
13. Lin, T. S., Avalos, B. R., Penza, S. L., Marcucci, G., Elder, P. J. and Copelan, E. A. (2002) Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplant, 29, pp. 763-767.
14. Vandenberghe, E., Pearce, R., Taghipour, G., Fouillard, L. and Goldstone, A. H. (1997) Role of a second transplant in the management of poor-prognosis lymphomas: A report from the European Blood and Bone Marrow Registry. J Clin Oncol, 15, pp. 1595-1600.
15. Horning, S. J., Hoppe, R. T., Breslin, S., Bartlett, N. L., Brown, B. W. and Rosenberg, S. A. (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol, 20, pp. 630-637.
16. Diehl, V. and Behringer, K. (2000) Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?. Cancer Invest, 24, pp. 713-717.